BACKGROUND: Universal prenatal HIV antibody testing, which does not detect acute HIV, is standard for pregnant women in the United States. Unrecognized HIV acquisition during pregnancy may result in higher rates of perinatal transmission. OBJECTIVE: To determine the prevalence of acute (antibody-negative) HIV infection in pregnant women and to assess the potential for prompt initiation of antiretroviral therapy to prevent perinatal transmission. METHODS: From 1 November 2002 to 30 April 2005, all publicly funded HIV testing sites participated in North Carolina's Screening and Tracing Active Transmission (STAT) Program, which retested all specimens that were HIV antibody negative for HIV RNA using specimen pooling. All patients with acute HIV infection were immediately traced for evaluation, confirmatory testing, counseling, and referral services. For this study, all pregnant women with acute HIV were immediately initiated onto antiretroviral therapy and followed prospectively for pregnancy outcomes. RESULTS: During the study period, 443 women were HIV positive by antibody testing; 15 were HIV antibody negative but positive by RNA assay and of these five were pregnant at the time of testing. The pregnant women received antiretroviral drugs and delivered HIV-uninfected infants. Maternal testing records of all six HIV-infected infants born in North Carolina showed three mothers with chronic HIV infection and three HIV antibody negative at private prenatal testing facilities. CONCLUSIONS: In resource-rich settings, a substantial proportion of residual perinatal transmission may be from HIV acquisition during pregnancy. Standard antibody tests miss acute HIV infection and so algorithms that include pooled HIV RNA testing may improve its detection and represent a further opportunity to prevent perinatal transmission.
BACKGROUND: Universal prenatal HIV antibody testing, which does not detect acute HIV, is standard for pregnant women in the United States. Unrecognized HIV acquisition during pregnancy may result in higher rates of perinatal transmission. OBJECTIVE: To determine the prevalence of acute (antibody-negative) HIV infection in pregnant women and to assess the potential for prompt initiation of antiretroviral therapy to prevent perinatal transmission. METHODS: From 1 November 2002 to 30 April 2005, all publicly funded HIV testing sites participated in North Carolina's Screening and Tracing Active Transmission (STAT) Program, which retested all specimens that were HIV antibody negative for HIV RNA using specimen pooling. All patients with acute HIV infection were immediately traced for evaluation, confirmatory testing, counseling, and referral services. For this study, all pregnant women with acute HIV were immediately initiated onto antiretroviral therapy and followed prospectively for pregnancy outcomes. RESULTS: During the study period, 443 women were HIV positive by antibody testing; 15 were HIV antibody negative but positive by RNA assay and of these five were pregnant at the time of testing. The pregnant women received antiretroviral drugs and delivered HIV-uninfectedinfants. Maternal testing records of all six HIV-infectedinfants born in North Carolina showed three mothers with chronic HIV infection and three HIV antibody negative at private prenatal testing facilities. CONCLUSIONS: In resource-rich settings, a substantial proportion of residual perinatal transmission may be from HIV acquisition during pregnancy. Standard antibody tests miss acute HIV infection and so algorithms that include pooled HIV RNA testing may improve its detection and represent a further opportunity to prevent perinatal transmission.
Authors: Brenna L Anderson; Mimi Ghosh; Christina Raker; John Fahey; Yan Song; Dwight J Rouse; Charles R Wira; Susan Cu-Uvin Journal: Am J Obstet Gynecol Date: 2012-04-30 Impact factor: 8.661
Authors: Mary Jo Trepka; Soumyadeep Mukherjee; Consuelo Beck-Sagué; Lorene M Maddox; Kristopher P Fennie; Diana M Sheehan; Maithri Prabhakar; Dan Thompson; Spencer Lieb Journal: South Med J Date: 2017-02 Impact factor: 0.954
Authors: Jane S Chen; Brian W Pence; Lisa Rahangdale; Kristine B Patterson; Claire E Farel; Amy L Durr; Amanda C Antono; Oksana Zakharova; Joseph J Eron; Sonia Napravnik Journal: AIDS Date: 2019-03-15 Impact factor: 4.177
Authors: Carly E Kelley; Sindy M Paul; Firoozeh M Vali; Jane M Caruso; Rose M Martin; Patricia L Fleming Journal: Public Health Rep Date: 2011 Jan-Feb Impact factor: 2.792
Authors: Allan W Taylor; Steven R Nesheim; Xinjian Zhang; Ruiguang Song; Lauren F FitzHarris; Margaret A Lampe; Paul J Weidle; Patricia Sweeney Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Bhavna H Chohan; Kenneth Tapia; Michele Merkel; Arphaxad C Kariuki; Brian Khasimwa; Agatha Olago; Richard Gichohi; Elizabeth M Obimbo; Dalton C Wamalwa Journal: J Acquir Immune Defic Syndr Date: 2013-07-01 Impact factor: 3.731
Authors: Jillian Pintye; Kristin M Beima-Sofie; Pamela A Makabong'O; Anne Njoroge; Susan Brown Trinidad; Renee A Heffron; Jared M Baeten; Connie Celum; Daniel Matemo; John Kinuthia; Maureen C Kelley; Grace C John-Stewart Journal: AIDS Patient Care STDS Date: 2018-07-23 Impact factor: 5.078